Name: Molgramostim Inhalation Solution in Autoimmune pulmonary alveolar proteinosis: Access and distribution
Published: 2026-09-14T15:39:06-04:00

Product information and disease description Product description Product information

Access and distribution

4 evidence topics · 4 sources

Anticipated specialty pharmacy distribution and patient assistance

“PANTHERx® Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI*” (opens the source at this quote in a new tab)
“If approved,” (opens the source at this quote in a new tab)
“comprehensive financial and insurance assistance.” (opens the source at this quote in a new tab)

Expanded access program authorization

“The Savara Early Access Program has been reviewed and allowed to proceed by the U.S. Food and Drug Administration (FDA)” (opens the source at this quote in a new tab)

Expanded access requests

“All requests must be submitted by a licensed pulmonologist.” (opens the source at this quote in a new tab)
“Requests for access are not a guarantee that access to molgramostim will be granted.” (opens the source at this quote in a new tab)

Expanded access dosing and follow-up

“Patients will dose molgramostim nebulizer solution 300 micrograms (mcg) once daily and be followed by their physician every 3 months” (opens the source at this quote in a new tab)